scPharmaceuticals
61 articles with scPharmaceuticals
-
scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
11/9/2021
scPharmaceuticals Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
-
scPharmaceuticals to Present at the Jefferies London Healthcare Conference
11/2/2021
scPharmaceuticals Inc. today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies London Healthcare Conference, which is being held in-person on November 16-17 and virtually November 18-19.
-
scPharmaceuticals Inc. Presents Late-breaking FREEDOM-HF Study Data at the Heart Failure Society of America Annual Scientific Meeting 2021
9/10/2021
scPharmaceuticals Inc. today announced that data from its recently-completed FREEDOM-HF clinical trial will be presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.
-
scPharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
9/1/2021
cPharmaceuticals Inc. today announced that John Tucker, president & chief executive officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021
-
scPharmaceuticals Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
8/11/2021
scPharmaceuticals Inc. today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
-
scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study
7/13/2021
Reduced average 30-day heart failure related costs by $17,753 per study subject in FUROSCIX ® arm compared to historically matched comparators.
-
scPharmaceuticals Inc. Announces Receipt of Written Minutes from Type C Meeting with the FDA Regarding Development of FUROSCIX®
7/1/2021
scPharmaceuticals Inc. (Nasdaq: SCPH), today announced that on June 30, 2021 the Company received the minutes from its Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the requirements for resubmission of the FUROSCIX New Drug Application (NDA).
-
scPharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
5/19/2021
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 EDT.
-
scPharmaceuticals Inc. Reports First Quarter 2021 Financial Results and Provides Business Update
5/12/2021
scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced financial results for the first quarter ended March 31, 2021 and provided a business update.
-
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/23/2021
Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million, sufficient to fund operations through potential FUROSCIX approval and launch, if approved, and into 2023
-
scPharmaceuticals to Present in Two Upcoming Investor Conferences
2/25/2021
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, will participate in two upcoming investor conferences
-
scPharmaceuticals Inc. Announces Results of Type A End-of-Review Meeting with FDA Regarding FUROSCIX® NDA
2/23/2021
No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million, sufficient to fund operations through potential FUROSCIX® approval and launch and into 2023
-
scPharmaceuticals Inc. Appoints Renowned Heart Failure Specialist William T. Abraham, M.D., to its Board of Directors
2/17/2021
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of William T. Abraham, M.D., to the company’s Board of Directors.
-
scPharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2/11/2021
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 10th Annual SVB Leerink Global Healthcare Conference
-
The U.S. FDA is plenty busy with COVID-19 vaccine Emergency Use Authorizations this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Here’s a look.
-
scPharmaceuticals Inc. Receives Complete Response Letter from FDA for FUROSCIX®CRL did not identify clinical deficiencies
12/7/2020
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced it received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) on December 3, 2020 regarding the Company’s New Drug Application (“NDA”) for FUROSCIX®.
-
scPharmaceuticals to Present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference
11/19/2020
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on Thursday, December 3 at 11:20am EST. A live
-
scPharmaceuticals Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
11/16/2020
Commercialization preparedness activities continuing ahead of December 30 PDUFA date for FUROSCIX® (furosemide injection) for subcutaneous administration
-
scPharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference
11/11/2020
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the Jefferies Virtual London Healthcare Conference
-
scPharmaceuticals Provides Business Update
10/8/2020
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today provided a business update on FUROSCIX ® , its investigational proprietary formulation of furosemide for subcutaneous administration. “As we look forward to our upcoming December 30, 2020 PDUFA date